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Stage IV non-small cell lung cancer is a fatal disease, with a median survival of 14 months. Systemic chemotherapy is the most
common approach. However the impact in overall survival and quality of life still a controversy.
Objectives: To determine differences in overall survival and quality of life among patients with stage IV non-small cell lung
cancer non-metastatic to the brain treated with best supportive care versus systemic chemotherapy.
Patients: From February 1990 through December 1995, 78 eligible patients were admitted with the diagnosis of stage IV non-
small cell lung cancer . Patients were divided in 2 groups: Group A (n=31 – treated with best supportive care ), and Group B (n=47
– treated with systemic chemotherapy).
Results: The median survival time was 23 weeks (range 5 – 153 weeks) in Group A and 55 weeks (range 7.4 – 213 weeks) in
Group B (p=0.0018). In both groups, the incidence of admission for IV antibiotics and need of blood transfusions were similar.
Patients receiving systemic chemotherapy were also stratified into those receiving mytomycin, vinblastin, and cisplatinum, n=25
and those receiving other combination regimens (platinum derivatives associated with other drugs, n=22). Patients receiving
mytomycin, vinblastin, and cisplatinum, n=25 had a higher incidence of febrile neutropenia and had their cycles delayed for longer
periods of time than the other group. These patients also had a shorter median survival time (51 versus 66 weeks, p=0.005).
Conclusion: In patients with stage IV non-small cell lung cancer, non-metastatic to the brain, chemotherapy significantly
increases survival compared with best supportive care.
DESCRIPTORS: Chemotherapy. Non-small cell lung cancer. Best supportive care. Mytomycim, vinblastin and
cisplatinum. Fatal disease.
Non-small cell lung carcinoma
(NSCLC) is a common tumor, with ap-
proximately half a million new cases
registered every year worldwide1.
Thirty to 40% of all newly admitted
patients present with disseminated
metastatic disease with a limited or pal-
liative role for localized surgical or ra-
diation therapy. For patients with this
advanced stage, chemotherapy (CT) is
the treatment of choice in most centers.
Response rates with most regimens
of chemotherapy range between 20%
and 30%2. Recently, the introduction of
new agents, such as vinorelbine or the
combination of cisplatinum or
cisplatinum derivatives with paclitaxel,
has resulted in higher response rates,
reaching 60% in some series3,4.
Those patients usually present a me-
dian survival of 6 months5. The impact
of chemotherapy on overall survival and
quality of life of patients with metastatic
NSCLC, as opposed to best supportive
care solely, is still widely debated. Sev-
eral studies have been published show-
ing a small, although statistically sig-
nificant, survival advantage for patients
treated with chemotherapy6-9. Meta-
analyses and randomized studies10-13
have demonstrated a clear benefit fol-
lowing systemic treatment, with one of
them reaching a survival advantage of
15 weeks 14. A subsequent study by the
same center showed reduced overall
medical costs for patients receiving
chemotherapy, mainly when less expen-
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sive regimens were administered15.
Other studies, however, did not report
any advantageous trend for chemo-
therapy2.
The present study evaluates clinical
outcomes of patients with stage IV
NSCLC, as well as the impact of dif-
ferent treatment modalities.
PATIENTS  AND  METHODS
A retrospective analysis was per-
formed using a prospective database.
To obtain a minimum follow-up of 5
years, the records were reviewed from
February 1990 to December 1995, with
histologically proven stage IV NSCLC
and with no demonstrable central ner-
vous system metastases on CT scan.
The treatment modality of each indi-
vidual patient was identified and reg-
istered (chemotherapy or best support-
ive care), as was the clinical outcome.
Study targets were defined as:
1. Survival analysis for both groups.
2. Assessment of quality of life, ac-
cording to the following criteria:
days of in hospital treatment, days
of intravenously administered anti-
biotics, necessity for blood and
blood derivative transfusion, and
number of febrile neutropenia epi-
sodes.
Eighty-six consecutive patients
were admitted during that period, with
8 patients being excluded from the fi-
nal analysis due to loss of follow-up
greater than 3 weeks after admission.
Survival time was calculated from
the date of diagnosis. Logistic regres-
sion was used to adjust for and deter-
mine the significance of the effect of
prognostic factors in the treatment
comparison of response. Cox’s propor-
tional hazard model was used to adjust
for and determine the significance of
the effect of prognostic factors in the
treatment comparisons of time to event
analyses (survival). All significance
levels were two sided16.
RESULTS
Thirty-one patients were treated
with best supportive care - BSC (Group
A), while 47 patients received chemo-
therapy and best supportive care - CT
(Group B). Patient characteristics of the
two groups are displayed in table 1.
BSC was defined as treatment of
pain, cough, dyspnea, palliative radio-
therapy, infections, and pleural effu-
sions.
Both groups were comparable for
age and sex. On the other hand, perfor-
mance status was significantly lower in
patients of Group A, with 26% of pa-
tients presenting with important health
problems, compared to 4% in Group B.
Patients in Group A more often under-
went palliative radiotherapy (n=17 –
54.8%), than patients of Group B
(n=26, 55.3%), although the difference
was not significant.
Histology was significantly differ-
ent between groups: Squamous cell
carcinoma was more frequently diag-
nosed in Group A, while adenocarci-
noma was the most frequent histology
in Group B.
Chemotherapy was not indicated in
patients of Group A for the following
reasons:
1. Palliative radiotherapy (n=9).
2. Patient’s decision (n=5).
3. Medical decision to observe as-
ymptomatic patients with ECOG
performance status of 3 and 4
(n=8).
4. Infection on admission (n=1).
5. Immediate necessity for palliation
(n=5) until significant symptoms.
6. Limiting comorbidity (cardiac fail-
ure, n=1, renal failure, n=2).
Median survival for Group A was
23 weeks, significantly lower than the
55 weeks for Group B (p=0.0018).
Figure 1 shows the overall survival
curve for all patients. Figure 2 shows
survival according to modality of treat-
ment.
Patients that received chemo-
therapy intended to treat metastatic dis-
ease were further divided into 2 sub-
groups, depending on the regimen
used: MVP (mitomycin, vinblastin, and
cisplatinum, n=25) considered the stan-
dard treatment in the institution at that
period, or other investigational chemo-
therapy regimens (including
cisplatinum derivatives in combination
with etoposide or paclitaxel, and the
combination of ifosfamide,
cisplatinum, and vinblastin, n=22). Pa-
tients that received MVP had a 51-
week median survival, significantly
lower than the 66 weeks for the other
group. Figure 3 shows the survival
Table 1 - Patient characteristics.
Best Supportive Care Chemotherapy
n = 31 n = 47
Age Median 62 years Median 57 years
Sex Male - 22 (71%) Male - 32 (68%)
Female - 9 (29%) Female - 15 (32%)
Performance Status* 3 and 4 - 8 (26%) 3 and 4 - 2 (4%)
Chest Radiotherapy 17 (54.8%) 26 (55.3%)
Squamous Cell 15 (48%) 11(23%)
Carcinoma
Adenocarcinoma 8 (26%) 30 (64%)
Others† 8 (26%) 6 (12%)
*ECOG Performance Status; † Others defined as: Large Cell Carcinoma and Undifferentiated
Carcinoma.
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curves according to the chemotherapy
regimen.
The overall response rate for chemo-
therapy was 19.1%, with no complete
response: nine patients had a partial ob-
jective response (19.1%), 21 patients
(44.7%) had stable disease, and 17 pa-
tients (36.2%) had progressive disease.
Figure 4 shows survival curves for pa-
tients according to type of response.
Performance status on admission
rendered the two groups too heteroge-
neous for a meaningful evaluation.
However, when patients with ECOG
PS 3-4 were excluded from both
groups, survival was still significantly
greater for patients treated with chemo-
therapy (51.2 weeks), compared to the
other group (33.8 weeks), p=0.002.
Patients in Group A had a median
in-hospital treatment time of 13 days,
similar to 16.5 days in Group B. No
significant differences were observed
for antibiotic administration and trans-
fusion episodes. Table 2 displays the
corresponding data.
Episodes of neutropenia occurred ex-
clusively in MVP patients (n=3 cycles).
This chemotherapeutic regimen was as-
sociated with significant delays between
cycles due to significant toxicity.
DISCUSSION
For patients with non-small cell
lung cancer (NSCLC), the prospect of
long-term survival is directly related to
the surgical resectability of the primary
tumor. At initial presentation, the great
majority of NSCLC have either locally
advanced inoperable disease, stage IV
metastatic disease, or comorbid medi-
cal conditions that render them unsuit-
able for surgical intervention. Because
of that, the vast majority of patients
with NSCLC are candidates for sys-
temic treatment with or without radio-
therapy. A large number of clinical tri-
als exploring combination chemo-
therapy in NSCLC have been per-
Figure 1 - Overall survival for all patients.
Figure 2 - Survival according to the treatment modality.
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formed. Several conclusions can be
drawn from a review of phase II and
phase III randomized trials performed
in NSCLC patients15,17,18: (1) overall re-
sponse rates usually range from 20%
to 30%; (2) complete responses are an
exception; (3) the majority of trials are
based on the combination of a
cisplatinum derivative and other drugs;
(4) the overall impact of combination
chemotherapy regimens on improved
survival is modest; (5) the majority of
patients rarely survive longer than 18
months, and most combination chemo-
therapy regimens are associated with
some type of toxicity (mainly nausea,
vomiting, and febrile neutropenia).
Although most of the trials of che-
motherapy in NSCLC show only a mar-
ginal improvement in medial length of
survival, the majority do show a trend
toward improved overall survival when
compared with best supportive care
(BSC). In a prospective randomized trial
conducted by Italian investigators12, 102
patients with NSCLC were randomized
to receive a combination of cisplatin,
cyclophosphamide, and vinblastin or to
receive BSC. In the group of patients re-
ceiving chemotherapy, the median over-
all survival was 8.5 months versus 4.0
months in the group receiving BSC
(p<.0001).
In another randomized trial con-
ducted by the National Cancer Institute
of Canada13, patients were randomized
to receive two different chemotherapy
regimens (vindesin and cisplatin or cy-
clophosphamide, doxorubicin, and
cisplatin) or BSC. Patients on the che-
motherapy arms had a median overall
survival of 32.6 and 24.7 weeks re-
spectively versus 17 weeks for the
group treated with BSC (p=0.05).
However, in two other studies, in-
cluding a large randomized trial involv-
ing 188 patients, no statistically signifi-
cant difference in survival was ob-
served, although an advantage for che-
motherapy was observed in some
patients subsets17,18.
Figure 3 - Survival according to the type of chemotherapy (MVP or other regimens).
Figure 4 - Survival according to the type of response to chemotherapy.
	
REV. HOSP. CLÍN. FAC. MED. S. PAULO 56(2):53-58, 2001MARCH-APRIL
Table 2 - Chemotherapy and quality of life.
Best Supportive Care Chemotherapy
n = 31 n = 47
In-hospital Treatment Median 13 days Median 16.5 days
(Range 1–70 days) (Range 1–57 days)
Antibiotic Administration Median 6 days Median 5 days
(Range 2–26 days) (Range 2–27 days)
Blood Transfusion Median 1 unit Median 2 units
(Range 0 – 8 units) (Range 0 – 16 units)
Febrile Neutropenia No episodes 3 episodes
In our study, the median sur-
vival for patients receiving BSC was 23
weeks, significantly lower than 55
weeks for the group receiving chemo-
therapy (p=0.002). Our data shows that
even when patients with a low ECOG
performance status are excluded from
analysis, overall survival is still higher
in patients treated with chemotherapy
compared to patients treated with best
supportive care only.
Measurement of quality of life
remains an important goal for investi-
gators treating patients with metastatic
lung cancer, since chemotherapy may
have a salutary or negative impact in-
dependent of how the survival curves
look19. In our study, the toxicity in the
group treated with chemotherapy was
mild and tolerable. Patients treated
with BSC had a median in-hospital
treatment time of 13 days, similar to
16.5 days in the group treated with
chemotherapy. We did not observe any
significant differences in terms of an-
tibiotic administration and transfusion
episodes.
The present study, which in-
cluded a balanced and adequate num-
ber of patients, indicates that patients
with metastatic non-small-cell lung
cancer can benefit from chemotherapy
with a statistically significant increase
in survival compared to best support-
ive care.
Whether the gains in life expect-
ancy are worth potential losses in qual-
ity of life from treatment side effects
is largely an individual patients choice.
The major challenge for oncologists
would be to identify and develop prop-
erly designed instruments to collect in-
formation on how much the expected
benefit is valued by the patients and to
involve patients in the decision of treat-
ment options, reflecting their own pref-
erences.
RESUMO RHCFAP/3036
ANELLI A e col. - Quimioterapia
versus melhor tratamento de supor-
te em câncer de pulmão estádio clí-
nico IV não metastático para o sis-
tema nervoso central. Rev. Hosp.
Clín. Fac. Med. S. Paulo 56 (2):53-
58, 2001.
O câncer de pulmão de células não
pequenas em estádio IV é uma doença
fatal, com uma sobrevida mediana de
seis meses. Quimioterapia é a aborda-
gem mais freqüente, apresentando um
impacto na sobrevida controverso e
questionável alteração na qualidade de
vida.
Objetivos: Comparar o impacto na
sobrevida global e na qualidade de vida
em pacientes portadores de câncer de
pulmão de células não pequenas, está-
dio IV, tratados com suporte clínico ou
quimioterapia.
Pacientes: Entre fevereiro de 1990
e dezembro de 1995, 78 pacientes (pts)
portadores de câncer de pulmão de cé-
lulas não pequenas estádio IV foram
admitidos. Os pacientes foram dividi-
dos em dois grupos: grupo A (n=31 –
tratados com suporte clínico) e grupo
B (n=47, tratados com quimioterapia).
Resultados: A sobrevida mediana
no grupo tratado com suporte clínico foi
de 23 semanas (variando de 5-153 se-
manas) e de 55 semanas no grupo tra-
tado com quimioterapia (variando de
7,4 a 213 semanas), p= 0,0018 – Qui-
quadrada. Em ambos grupos, a incidên-
cia de internações hospitalares para a
administração intravenosa de antibióti-
cos e hemoderivados foi similar. Paci-
entes recebendo quimioterapia, foram
estratificados entre àqueles que rece-
beram mitomicina, vinblastina e
cisplatina, n=25 e àqueles recebendo
outros regimes (derivados de platina,
associados à outras drogas, n= 22). Pa-
cientes recebendo mitomicina,
vinblastina e cisplatina, n=25 apresen-
taram uma incidência mais alta de
neutropenia febril e tiveram atrasos mais
longos entre os ciclos de quimioterapia,
quando comparados aos pacientes do
outro grupo. Pacientes recebendo
mitomicina, vinblastina e cisplatina,
n=25, também apresentaram uma pior
sobrevida mediana (51 versus 66 sema-
nas, p= 0,005 – Qui-quadrado).
Conclusões: Em pacientes com
câncer de pulmão de células não pe-
quenas, estádio IV, não metastático
para os pulmões, o uso de quimio-
terapia aumenta a sobrevida de maneira
estatisticamente significativa, quando
comparado aos cuidados de suporte.
DESCRITORES: Quimioterapia.
Câncer de pulmão de células não pe-
quenas. Suporte clínico. Metomicina,
vinblastina e cisplatina. Doença fatal.
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